Navigation Links
Labopharm to present at Cowen 30th Annual Health Care Conference
Date:3/3/2010

LAVAL, QC, March 3 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the Cowen and Company 30th Annual Health Care Conference at The Boston Marriott Copley Place, on Tuesday, March 9, 2010 at 1:30 p.m. ET.

Interested parties may access the live webcast for this presentation by visiting the "Events" section of the homepage of the Company's website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for 30 days.

About Labopharm Inc.

Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. Its second product, OLEPTRO(TM), a novel formulation of trazodone for the treatment of major depressive disorder in adults, has received regulatory approval in the U.S. and is under regulatory review in Canada. Labopharm has initiated the European regulatory approval process for its third product, a twice-daily formulation of tramadol-acetaminophen. The Company also has a pipeline of follow-on products in both pre-clinical and clinical development.

SOURCE Labopharm Inc.

Back to top
'/>"/>
SOURCE Labopharm Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm announces underwriters exercise of over-allotment option for recent public offering
2. Labopharm announces closing of US$20 million public offering of units
3. Labopharm announces pricing of US$20 million public offering of units
4. Labopharm settles $1 million draw down under standby equity distribution agreement
5. Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe
6. Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement
7. Labopharm Reports Results for Third Quarter Fiscal 2009
8. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
9. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
10. Labopharm submits response to FDA for novel antidepressant
11. Labopharm Reports Results for Second Quarter Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, ... and 31st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... being discussed by President Donald Trump and the rest of the world. Donald Trump ... peace talks in the continuous battle between Israel and Palestine. The world’s eyes are ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral ... new, informational blog post on insurance options. If a Bay Area patient has to ... save time and money. Visiting an in-network provider for a second opinion can ensure ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
Breaking Medicine Technology: